{
  "id": "warfarin_management_multipleChoice_v1",
  "type": "multipleChoice",
  "stem": "A patient with atrial fibrillation who takes warfarin presents with generalized bruising and an INR of 4.8. The patient's vital signs are stable, and there is no active bleeding. Which action should the nurse anticipate the healthcare provider will prescribe?",
  "options": [
    {
      "id": "a",
      "text": "Administer 10 units of fresh frozen plasma (FFP) intravenously (IV) immediately."
    },
    {
      "id": "c",
      "text": "Administer vitamin K 10 mg by slow IV infusion."
    },
    {
      "id": "d",
      "text": "Instruct the patient to immediately increase their intake of green leafy vegetables."
    },
    {
      "id": "b",
      "text": "Withhold the next dose of warfarin and monitor for signs of bleeding."
    }
  ],
  "correctOptionId": "b",
  "pedagogy": {
    "bloomLevel": "analyze",
    "cjmmStep": "generateSolutions",
    "nclexCategory": "Pharmacological and Parenteral Therapies",
    "difficulty": 3,
    "topicTags": [
      "Warfarin",
      "INR",
      "Anticoagulation",
      "Atrial Fibrillation",
      "Pharmacology"
    ]
  },
  "rationale": {
    "answerBreakdown": [
      {
        "optionId": "a",
        "content": "Incorrect. Fresh frozen plasma (FFP) contains all coagulation factors and is used for immediate reversal in life-threatening hemorrhage or before emergency surgery. Risks include transfusion-associated circulatory overload (TACO) and transfusion-related acute lung injury (TRALI). For a stable patient with an INR of 4.8 and no active bleeding, the risks of FFP outweigh the benefits.",
        "scoring": -1
      },
      {
        "optionId": "c",
        "content": "Incorrect. Intravenous (IV) vitamin K (phytonadione) promotes the synthesis of functional clotting factors. It is too aggressive for an INR of 4.8 without significant bleeding and is typically reserved for INRs >10.0 or active bleeding. Rapid reversal can cause a prothrombotic state in patients with atrial fibrillation, increasing the risk of stroke. Anaphylactoid reactions are also a risk.",
        "scoring": -1
      },
      {
        "optionId": "d",
        "content": "Incorrect. Dietary changes are ineffective for the acute management of a supratherapeutic INR. Consistent vitamin K intake is crucial for long-term warfarin stability, but a sudden increase will not lower the INR quickly or predictably. This destabilizes future dosing by creating a fluctuating vitamin K baseline.",
        "scoring": -1
      },
      {
        "optionId": "b",
        "content": "Correct. For an INR between 4.5 and 10.0 without active bleeding, guidelines recommend withholding 1-2 doses of warfarin. Warfarin's long half-life (36-42 hours) allows the plasma concentration to decrease naturally. The liver resumes the synthesis of vitamin K-dependent clotting factors, gradually lowering the INR back to the therapeutic range (2.0-3.0 for atrial fibrillation) without the risk of over-correction.",
        "scoring": 1
      }
    ],
    "pathophysiology": "Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1) in the liver, preventing vitamin K recycling, which is essential for activating clotting factors II, VII, IX, and X. An INR of 4.8 indicates significant suppression, creating a risk of hemorrhage. In a stable patient, withholding warfarin allows the natural synthesis of clotting factors to resume, safely correcting the coagulopathy over 24-48 hours. Active reversal agents can induce a prothrombotic rebound, which is dangerous in atrial fibrillation.",
    "clinicalPearls": "Monitor for signs of bleeding (e.g., hematuria, melena, epistaxis, gingival bleeding). Educate the patient about consistent vitamin K intake and the importance of regular INR monitoring. If active bleeding occurs, notify the healthcare provider immediately. Ensure the patient understands the signs and symptoms of stroke and the importance of seeking immediate medical attention if they occur.",
    "questionTrap": "The trap is 'intervention bias'—administering FFP or vitamin K for an abnormal lab value and bruising. Differentiate between bruising (evidence of coagulopathy) and active bleeding (e.g., GI bleed). For a stable patient with a moderately elevated INR, 'masterful inactivity'—withholding medication and monitoring—is often the best approach.",
    "mnemonics": "HOLD for elevated INR without bleeding:\n- H: High INR (4.5-10.0).\n- O: Observe for bleeding.\n- L: Limit reversal agents (no vitamin K/FFP).\n- D: Discontinue (hold) the next dose(s) and reassess INR.",
    "correct": "Clinical rationale pending deep clinical alignment."
  },
  "scoring": {
    "method": "dichotomous",
    "maxPoints": 1
  },
  "sbar": {
    "situation": "Patient with atrial fibrillation on warfarin presents with generalized bruising and an INR of 4.8. Vital signs are stable, and there is no active bleeding.",
    "background": "Patient is on warfarin for atrial fibrillation. Current INR is significantly elevated. No recent changes in medication or diet reported.",
    "assessment": "Patient is stable with generalized bruising, INR 4.8, and no active bleeding. The risk for bleeding is increased due to the supratherapeutic INR.",
    "recommendation": "Recommend withholding the next dose of warfarin and monitoring the INR daily. Assess for any signs of active bleeding. Consider repeating the INR in 24 hours to assess the trend. Educate the patient on the signs and symptoms of bleeding and when to seek immediate medical attention. Contact the healthcare provider if the INR continues to rise or if bleeding occurs.",
    "time": "1400"
  },
  "sentinelStatus": "healed_v2026_v11"
}